MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Company has scheduled a conference call for analysts and investors on Wednesday, May 31, 2023 at 4:00 P.M. (IST) on the Audited (standalone and consolidated) financial results of the Company for the quarter and year ended March 31, 2023. MARKSANS PHARMA LTD. - 524404 - Board Meeting Intimation for Approval Of Audited Financial Results And Dividend
MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2023 ,inter alia, to consider and approve the Audited Financial Results of the Company (both Standalone and Consolidated) for the Quarter and Year ended 31st March, 2023. The Board of Directors will also consider recommendation of dividend, if any, for the Financial Year 2022-23. MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith copies of the newspaper advertisement confirming dispatch of the Postal Ballot Notice published today in Business Standard (English) and Lakshadeep (Marathi) newspapers. MARKSANS PHARMA LTD. - 524404 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Marksans Pharma Limited is conducting a Postal Ballot through electronic means by remote e-voting process for seeking approval of the members, by way of a Special Resolution, for re-appointment of Mr. Digant Mahesh Parikh (DIN: 00212589) as an Independent Director of the Company. MARKSANS PHARMA LTD. - 524404 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company MARKSANS PHARMA LTD. 2 CIN NO. L24110MH1992PLC066364 3 Report filed for FY 2022-2023 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* FY 2022-23, FY 2023-24 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) NA 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* NA Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)FY 2021-22, FY 2022-23 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Harshavardhan PanigrahiDesignation :-Company Secretary Name of the Chief Financial Officer :- Jitendra Sharma Designation : -Chief Financial Officer Date: 24/04/2023 MARKSANS PHARMA LTD. - 524404 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyMARKSANS PHARMA LTD. 2CIN NO.L24110MH1992PLC066364 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Harshavardhan Panigrahi Designation: Company Secretary EmailId: harshavardhan@marksanspharma.com Name of the Chief Financial Officer: Jitendra Sharma Designation: Chief Financial Officer EmailId: jitendra@marksanspharma.com Date: 24/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. MARKSANS PHARMA LTD. - 524404 - Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
We enclose herewith Certificate issued by Sanjay Dholakia & Associates, Practising Company Secretaries for the year ended 31st March, 2023 as required under Regulation 40(9) & 40(10) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Enclosed herewith kindly find the press release dated 19th April, 2023 of the Company MARKSANS PHARMA LTD. - 524404 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st March, 2023. MARKSANS PHARMA LTD. - 524404 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby furnish details of issue of duplicate share certificate against loss of share certificate on April 12, 2023 received from our Registrar and Transfer Agent, Bigshare Services Private Limited.